title: [Effect of beta-Blocker Bisoprolol on Function of Hibernating Myocardium in Patients With Chronic Heart Failure of Ischemic Etiology].
abstract: OBJECTIVE
  To elucidate effect of beta-blocker bisoprolol on hibernating myocardium in patients with congestive heart failure (CHF) of ischaemic etiology without concomitant use of angiotensin converting enzyme inhibitors.
  
  
  METHODS
  Men (n=21, mean age 51,1+/-2,3 years) with NYHA class II-III congestive heart failure were divided into 2 groups according to results of dobutamine stress-echocardiography: with (group I, n=11), and without (group II, n=10) hibernating myocardium. All patients received bisoprolol (mean daily dose 8.9+/-0.5 mg) for 6 months.
  
  
  RESULTS
  In both groups treatment was associated with NYHA class lowering (36.7%, p=0.002, in group 1, and 33.5%, p=0.02, in group II), significant increase of tolerance to physical exercise, improvement of quality of life. Left ventricular ejection fraction significantly increased (+10.5%, p=0.008) in patients with hibernating myocardium and practically did not change in group II (+4,8%, p=0,08). Meanwhile number of normokinetic zones increased by 94,4% in group I (p=0.008) and by 37,5% (p=0,02) in group II. This was associated with reduction of wall motion score index by 10.6%, p=0,009, and 8.2%, p=0,009, respectively.
  
  
  CONCLUSIONS
  These results evidence for efficacy of treatment of patients with heart failure and hibernating myocardium with beta-blocker bisoprolol. In patients with heart failure of ischemic etiology bisoprolol facilitates transition of a part of myocardium from hypokinetic to normokinetic state.
authors.affiliation: Volgograd Medical University, Center of Cardiology.
authors.forename: V V
authors.initials: VV
authors.lastname: Ivanenko
authors.forename: N V
authors.initials: NV
authors.lastname: Riazantseva
authors.forename: D L
authors.initials: DL
authors.lastname: Tarasov
authors.forename: Iu M
authors.initials: IuM
authors.lastname: Lopatin
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D017298:Bisoprolol / Q000627:therapeutic use; D006333:Heart Failure; D006801:Humans; D009206:Myocardium; D011788:Quality of Life
chemical_list: D000319:Adrenergic beta-Antagonists; D017298:Bisoprolol